Nanotechnology in cancer treatment

被引:0
作者
Maria, Mironidou-Tzouveleki [1 ]
Konstantinos, Imprialos [1 ,2 ]
Athanasios, Kintsakis [3 ]
机构
[1] Aristotle Univ Thessaloniki, Sch Med, Lab Pharmacol A, Thessaloniki, Greece
[2] Aristotle Univ Thessaloniki, Sch Med, Dept Thessaloniki, Sci Soc Hellen Med Students, Thessaloniki, Greece
[3] Aristotle Univ Thessaloniki, Polytech Fac, Elect & Comp Engn, Thessaloniki, Greece
来源
BIOSENSING AND NANOMEDICINE IV | 2011年 / 8099卷
关键词
nanotechnology; cancer; treatment; nanosystems; anticancer agents; DRUG-DELIVERY; CARBON NANOTUBES; THERMAL THERAPY; NANOPARTICLES; PHARMACOKINETICS; LIPOSOMES; DIAGNOSIS; BINDING; SIZE;
D O I
10.1117/12.898643
中图分类号
TM [电工技术]; TN [电子技术、通信技术];
学科分类号
0808 ; 0809 ;
摘要
The purpose of this paper is to analyze the current evolutions on nanotechnology and its applications on cancer theragnostics. Rapid advances and emerging technologies in nanotechnology are having a profound impact on cancer treatment. Applications of nanotechnology, which include liposomes, nanoparticles, polymeric micelles, dendrimers, nanocantilever, carbon nanotubes and quantum dots have significantly revolutionized cancer theragnostics. From a pharmaceutical viewpoint, it is critical that the biodistribution of active agents has to be controlled as much as possible. This aspect is vital in order to assure the proper efficiency and safety of the anticancer agents. These biocompatible nanocomposites provide specific biochemical interactions with receptors expressed on the surface of cancer cells. With passive or active targeting strategies, an increased intracellular concentration of drugs can be achieved in cancer cells, while normal cells are being protected from the drug simultaneously. Thus, nanotechnology restricts the extent of the adverse effects of the anticancer therapy. Treatment for metastatic breast cancer, sarcoma in AIDS patients, ovarian and lung cancer is already on market or under final phases of many clinical trials, showing remarkable results. As nanotechnology is perfected, side effects due to normal cell damage will decrease, leading to better results and lengthening patient's survival.
引用
收藏
页数:9
相关论文
共 39 条
[1]  
[Anonymous], EPITHEORESE KLIN PHA
[2]  
[Anonymous], ARISTOTLE U MED J
[3]   Nanoparticle and targeted systems for cancer therapy [J].
Brannon-Peppas, L ;
Blanchette, JO .
ADVANCED DRUG DELIVERY REVIEWS, 2004, 56 (11) :1649-1659
[4]   Therapeutic nanoparticles for drug delivery in cancer [J].
Cho, Kwangjae ;
Wang, Xu ;
Nie, Shuming ;
Chen, Zhuo ;
Shin, Dong M. .
CLINICAL CANCER RESEARCH, 2008, 14 (05) :1310-1316
[5]   Quantum dots in biomedical applications: advances and challenges [J].
Cinteza, Ludmila Otilia .
JOURNAL OF NANOPHOTONICS, 2010, 4
[6]   Cancer nanotechnology: Opportunities and challenges [J].
Ferrari, M .
NATURE REVIEWS CANCER, 2005, 5 (03) :161-171
[7]   Organic functionalization of carbon nanotubes [J].
Georgakilas, V ;
Kordatos, K ;
Prato, M ;
Guldi, DM ;
Holzinger, M ;
Hirsch, A .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2002, 124 (05) :760-761
[8]   Nanotechnology for cancer diagnostics: promises and challenges [J].
Grodzinski, Piotr ;
Silver, Mike ;
Molnar, Linda K. .
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2006, 6 (03) :307-318
[9]   Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance [J].
Hirsch, LR ;
Stafford, RJ ;
Bankson, JA ;
Sershen, SR ;
Rivera, B ;
Price, RE ;
Hazle, JD ;
Halas, NJ ;
West, JL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (23) :13549-13554
[10]  
Howlader N., 2011, SEER cancer statistics review, 1975-2008